Amgen to Pay $95 Million to Settle Suit Over Failure to Disclose Aranesp Data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Amgen Inc. agreed to pay $95 million to settle a class action suit filed by investors who bought the company’s securities between April 2004 and May 2007.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 
As he addressed FDA employees, HHS Secretary Robert F. Kennedy Jr. described the Trump era as a “generational opportunity to make the regulatory agency live up to its foundational ideals” and emerge from the morass of what he described as the “deep state.”
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login